US 11,707,408 B2
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
Steven Edward DeMartino, Painted Post, NY (US); John Stephen Peanasky, Big Flats, NY (US); Robert Anthony Schaut, Painted Post, NY (US); and Wendell Porter Weeks, Corning, NY (US)
Assigned to CORNING INCORPORATED, Corning, NY (US)
Filed by CORNING INCORPORATED, CORNING, NY (US)
Filed on Oct. 25, 2012, as Appl. No. 13/660,508.
Claims priority of provisional application 61/656,998, filed on Jun. 7, 2012.
Claims priority of provisional application 61/551,163, filed on Oct. 25, 2011.
Prior Publication US 2013/0101596 A1, Apr. 25, 2013
This patent is subject to a terminal disclaimer.
Int. Cl. A61J 1/14 (2023.01); A61J 1/00 (2023.01); A61K 39/395 (2006.01); C03C 3/087 (2006.01); C03C 3/091 (2006.01); C03C 21/00 (2006.01); C03C 4/20 (2006.01); A61J 1/06 (2006.01); A61K 38/17 (2006.01); A61K 38/19 (2006.01); A61K 38/28 (2006.01); A61K 31/403 (2006.01); A61K 38/18 (2006.01); C07K 16/24 (2006.01)
CPC A61J 1/1468 (2015.05) [A61J 1/00 (2013.01); A61J 1/065 (2013.01); A61K 31/403 (2013.01); A61K 38/17 (2013.01); A61K 38/1816 (2013.01); A61K 38/193 (2013.01); A61K 38/28 (2013.01); A61K 39/3955 (2013.01); C03C 3/087 (2013.01); C03C 3/091 (2013.01); C03C 4/20 (2013.01); C03C 21/002 (2013.01); C07K 16/241 (2013.01); Y02A 50/30 (2018.01); Y10T 428/131 (2015.01)] 33 Claims
OG exemplary drawing
 
1. A delamination resistant pharmaceutical container comprising a pharmaceutical composition stored in the container comprising an active pharmaceutical ingredient, wherein the pharmaceutical container comprises a glass composition comprising:
SiO2 in a concentration greater than 74 mol. %;
ZrO2 in a concentration less than 1 mol. %;
alkaline earth oxide comprising MgO and CaO, wherein CaO is present in an amount greater than or equal to 0.1 mol. % and less than or equal to 1.0 mol. % relative to the glass composition, and a ratio (CaO (mol. %)/(CaO (mol. %)+MgO (mol. %))) is less than or equal to 0.5; and
Y mol. % alkali oxide, wherein the alkali oxide comprises Na2O in an amount greater than 8 mol. %,
wherein the glass composition is free of boron and compounds of boron, and
wherein the pharmaceutical composition comprises Adalimumab.